Affimed (NASDAQ:AFMD) Share Price Crosses Above 50 Day Moving Average of $5.46

Affimed (NASDAQ:AFMD)’s share price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.46 and traded as high as $5.65. Affimed shares last traded at $5.33, with a volume of 99,631 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Affimed in a research report on Tuesday, January 2nd. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Affimed currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Affimed Price Performance

The company’s 50 day moving average price is $5.46 and its 200-day moving average price is $4.89. The stock has a market cap of $79.58 million, a P/E ratio of -0.63 and a beta of 2.07. The company has a quick ratio of 3.67, a current ratio of 3.70 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On Affimed

Large investors have recently modified their holdings of the business. Advisor Group Holdings Inc. raised its stake in shares of Affimed by 258.3% during the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 6,464 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Affimed by 30.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 3,202 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Affimed during the first quarter valued at $102,000. BNP Paribas Arbitrage SA raised its stake in Affimed by 213.6% during the second quarter. BNP Paribas Arbitrage SA now owns 31,557 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 21,493 shares during the last quarter. Finally, UBS Group AG bought a new position in Affimed during the fourth quarter worth $41,000. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.